Development of and recovery from acute kidney injury after cardiac surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic ANG-3777
The Journal of Thoracic and Cardiovascular Surgery · 2025-10 · 170 (4) · 1125-1132.e2
DOI: 10.1016/j.jtcvs.2024.11.024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025-10. Verfasst von Sabry S Ayad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Outcomes Research Department, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: saayad@ccf.org. Hauptthemen laut MEDLINE: Acute Kidney Injury, Cardiac Surgical Procedures, Hepatocyte Growth Factor, Cardiopulmonary Bypass. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Vifor, Angion, Envision.
Abstract (Originalsprache)
OBJECTIVES: To investigate the safety and efficacy of ANG-3777, a hepatocyte growth factor mimetic, in mitigating the risk of acute kidney injury (AKI) in patients undergoing cardiac surgery with cardiopulmonary bypass. METHODS: In this double-blind placebo-controlled study (Guard Against Renal Damage [GUARD]), patients were randomized to receive intravenous ANG-3777 2 mg/kg or placebo once daily for 4 days. The primary end point was severity of AKI, measured by mean area under the concentration-time curve on percent increase in serum creatinine from days 2 to 6. Secondary end points included the proportions of patients who developed major adverse kidney events by day 30 or 90 and the percentage of patients diagnosed with AKI through day 5. RESULTS: In total, 259 patients received study treatment (ANG-3777, n = 129; placebo, n = 130). Through day 6, there was no significant difference in least-squares mean change in serum creatinine between ANG-3777 and placebo (1.1%; 95% confidence interval, -6.2 to 8.4; P = .77), or in proportions of patients who developed major adverse kidney events by day 30 (18.6% vs 16.2%; P = .60) or day 90 (14.7% vs 21.5%; P = .16). Similar proportions of patients were diagnosed with AKI through day 5 (ANG-3777, 47.3%; placebo, 48.5%); however, exploratory analysis revealed more patients diagnosed with AKI postoperatively showed signs of recovery after treatment with ANG-3777 than placebo. Overall, ANG-3777 was well tolerated, with similar incidences of treatment-emergent adverse events between treatment arms. CONCLUSIONS: Findings from this study do not support the efficacy of ANG-3777 in preventing the development of AKI after cardiopulmonary bypass.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Outcomes Research Department, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: saayad@ccf.org.
- Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, Fla.
- Department of Cardiology, Sands-Constellation Heart Institute, Rochester Regional Health, Rochester, NY.
- Department of Anesthesiology, Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine, Winston-Salem, NC.
- Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, Calif.
- Angion Biomedica, Uniondale, NY.
Förderung
- CSL Vifor
- Angion
- Envision
- California State Library
Zitieren
APA
Ayad, S. S., Beaver, T., Corteville, D., Swaminathan, M., Pearl, R. G., Aslam, S., Csomor, P. A., Alperovich, G., & Neylan, J. (2025). Development of and recovery from acute kidney injury after cardiac surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic ANG-3777. The Journal of Thoracic and Cardiovascular Surgery, 170(4), 1125-1132.e2. https://doi.org/10.1016/j.jtcvs.2024.11.024
Vancouver
Ayad SS, Beaver T, Corteville D, Swaminathan M, Pearl RG, Aslam S, et al. Development of and recovery from acute kidney injury after cardiac surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic ANG-3777. The Journal of Thoracic and Cardiovascular Surgery. 2025;170(4):1125-1132.e2. doi:10.1016/j.jtcvs.2024.11.024
BibTeX
@article{Ayad2025,
author = {Ayad, Sabry S and Beaver, Thomas and Corteville, David and Swaminathan, Madhav and Pearl, Ronald G and Aslam, Shakil and Csomor, Philipp Andreas and Alperovich, Gabriela and Neylan, John},
title = {Development of and recovery from acute kidney injury after cardiac surgery: Randomized phase 2 trial of the hepatocyte growth factor mimetic ANG-3777},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2025},
volume = {170},
number = {4},
pages = {1125--1132.e2},
doi = {10.1016/j.jtcvs.2024.11.024}
}
EUVIMED